Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Pre-clinical studies suggest pacritinib can impact multiple MYD88Mut pro-survival pathways in Waldenström macroglobulinemia models, including IRAK1, JAK2, HCK, and BTK at achievable levels, and cooperate with other agents.”
Title: Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia
Authors: Shirong Liu, Amanda Kofides, Xia Liu, John M. Hatcher, Hao Sun, Nicholas Tsakmaklis, Alberto Guijosa, Maria L. Guerrera, Dominic Pizzarella, Abigail L. Peachey, Christopher J. Patterson
You can read the Full Article in the British Journal of Haematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
